Venous Thromboembolism Treatment Market

Posted by ahila on May 4th, 2018

Venous thromboembolism is a disease caused by the clotting of blood in the blood vessel which leads to restriction of blood flow within the circulatory system. Venous thromboembolism is classified into pulmonary embolism and deep vein thrombosis. Deep vein thrombosis is mainly occurred due to the clotting of the blood in the deep vein (commonly in the leg). The formed DVT clot breaks off and flows to the lungs known as pulmonary embolism which is a severe complication of deep vein thrombosis (DVT). Venous thromboembolism commonly occurs in aged persons with more than 60 years. People with overweight, persons with thicker blood and the persons suffering from autoimmune disorders such as (lupus, rheumatoid arthritis etc.) or cancer are at higher risk of venous thromboembolism. Venous thromboembolism can cause chronic complications, such as post-thrombotic syndrome (PTS) or chronic thromboembolic pulmonary hypertension (CTEPH). The symptoms associated with the venous thromboembolism include dilated blood veins in legs and chest, oedema, fever, tachycardia, and dyspnoea. Lower extremities are the most common site for DVT, but other locations affected include the mesenteric, upper extremities, pelvic veins, and cerebral veins.

The venous thromboembolism treatment market is growing at a significant CAGR due to increase in geriatric population. Rise in the government expenditure, increase in the incidence of venous thromboembolism are fuelling the venous thromboembolism treatment market. Furthermore, increase in surgical procedures such as hip and knee replacements that are risk factors for venous thromboembolism conditions, growing patient awareness venous thromboembolism conditions expected to boost the venous thromboembolism treatment market growth over the forecast period.  However, high cost of deep vein thrombosis treatment, high unmet needs of currently available treatment procedures, and adverse effects associated with drugs hinder the growth of venous thromboembolism treatment market. Similarly, stringent regulatory approvals, the presence of alternatives treatments such as thrombectomy and percutaneous techniques are hindering the growth of venous thromboembolism treatment market over the forecast period.

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-venous-thromboembolism-treatment-market/#ulp-4H8Z4LpNMLEuOnnx

The venous thromboembolism treatment market is segmented on the basis of drug type, disease type, and distribution channel

Based on drug type, venous thromboembolism treatment market is segmented into the following:

  • Factor Xa inhibitors
  • Thrombolytic therapy
  • Plasminogen activators
  • Fondaparinux
  • Dabigatran
  • Warfarin

Based on disease type, the venous thromboembolism treatment market is segmented into the following:

  • Deep vein thrombosis
  • Pulmonary embolism

Based on distribution channel, the venous thromboembolism treatment market is segmented into the following:

  • Hospital pharmacies
  • Online Pharmacies
  • Retail pharmacies

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/global-venous-thromboembolism-treatment-market/#ulp-c654SbFYO64MsOhu

Like it? Share it!


ahila

About the Author

ahila
Joined: March 20th, 2018
Articles Posted: 168

More by this author